Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Tokyo Big Sight

Nov 12, 2017 9:30 AM - Nov 14, 2017 5:30 PM

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

14th DIA Japan Annual Meeting 2017

[V4-S3] What is the Role of Medical Science Liaison (MSL) as New Function of Pharmaceutical Company?

Session Chair(s)

Koji  Iwasaki, PhD

Koji Iwasaki, PhD

Professor, Academic Clinical Research Center,

Osaka University Hospital, Japan

The pharmaceutical companies are starting to establish medical science liaison (MSL) as the new type of job to assume and exchange medical scientific information. In this session, we will discuss an appropriate profit of the drug information about an activity of MSLs In addition to catch the situation of MSL activities in the pharmaceutical company, we will clarify recognition of MSLs by Academia and MHLW. And then we discuss around the future appropriate drug information and the talent of MSLs.

Speaker(s)

Masaru  Iwasaki, MD, PhD

The Role of MSL - Expectation from Academia -

Masaru Iwasaki, MD, PhD

University of Yamanashi, Japan

Vice President, Head of Center for Advancing Clinical Research (CACR)

Yoshihiko  Otoguro

The Positioning and Activity Principles of MSL -EFPIA Japan-

Yoshihiko Otoguro

European Federation of Pharmaceutical Industries and Associations, Japan

Corporate Ethics Working Group, Governance and Legal Committee

Michiko  Tomiyasu

MSL: Their Role and What They Should be Equipped for

Michiko Tomiyasu

Sanofi K.K., Japan

Manager, Medical Affairs

Yoshifumi  Banzai, PhD

Expectation to Medical Science Liaison (MSL) in the Utilization of Drug Information from Regulatory Authorities

Yoshifumi Banzai, PhD

Ministry of Health, Labour and Welfare (MHLW), Japan

Deputy Director, Compliance and Narcotics Division

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.